UK MODERN SLAVERY ACT DISCLOSURE

This statement is made in accordance with Section 54 of the Modern Slavery Act 2015 for BioCryst UK Limited (“BioCryst UK”).

Our Organisation
BioCryst UK is part of the Neopharmed Gentili S.p.A. group following the acquisition of BioCryst’s European ORLADEYO® business. Neopharmed Gentili is a leading Italian pharmaceutical company focused on high-value therapeutic areas, including specialty and rare diseases, and expanding its commercial footprint across Europe. BioCryst UK supports the commercialisation and promotion of orphan and rare-disease medicinal products, including ORLADEYO®, through medical, regulatory and commercial activities in line with UK laws and industry standards.

Our Commitment
We are committed to conducting business ethically, lawfully, and with respect for human rights. All employees must comply with the group Code of Conduct and Ethics, which prohibits any form of forced labour, exploitation or human trafficking. Concerns may be raised confidentially or anonymously via a supplier Compliance Hotline, with all reports investigated appropriately.

Due Diligence Measures

During the reporting period we worked to strengthen supplier screening and oversight, including:

Training and Awareness

We worked with our primary supplier to expanded awareness through Forced Labor Awareness training, delivered live to the Supply Chain function within our supply chain and made available via ComplianceWire.

Continuous Improvement

We remain committed to enhancing our approach through:

Our Position
BioCryst UK has a zero-tolerance approach to modern slavery, forced labour and human trafficking within our organisation and our supply chains. We will continue to take steps to identify, prevent and address these risks.

Approved by the Board of Directors of BioCryst UK Limited on 8 December 2025

A black signature on a white background with stylized cursive writing.

Luke Robinson
General Manager